Relay Therapeutics (RLAY) Competitors $4.46 +0.14 (+3.24%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RLAY vs. ACAD, VCEL, XENE, MLTX, MOR, DNLI, SWTX, MRUS, ZLAB, and BHCShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Denali Therapeutics (DNLI), SpringWorks Therapeutics (SWTX), Merus (MRUS), Zai Lab (ZLAB), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. ACADIA Pharmaceuticals Vericel Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys Denali Therapeutics SpringWorks Therapeutics Merus Zai Lab Bausch Health Companies ACADIA Pharmaceuticals (NASDAQ:ACAD) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Does the MarketBeat Community believe in ACAD or RLAY? ACADIA Pharmaceuticals received 834 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 73.14% of users gave ACADIA Pharmaceuticals an outperform vote while only 69.41% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformACADIA PharmaceuticalsOutperform Votes89373.14% Underperform Votes32826.86% Relay TherapeuticsOutperform Votes5969.41% Underperform Votes2630.59% Do institutionals and insiders believe in ACAD or RLAY? 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, ACAD or RLAY? ACADIA Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$726.44M4.02-$61.29M$0.7822.53Relay Therapeutics$25.55M29.22-$341.97M-$2.61-1.71 Is ACAD or RLAY more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Relay Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals13.83% 25.83% 14.71% Relay Therapeutics N/A -45.75%-40.75% Which has more volatility & risk, ACAD or RLAY? ACADIA Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Do analysts recommend ACAD or RLAY? ACADIA Pharmaceuticals currently has a consensus price target of $25.25, suggesting a potential upside of 43.71%. Relay Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 359.64%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.59Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Does the media favor ACAD or RLAY? In the previous week, Relay Therapeutics had 1 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 15 mentions for Relay Therapeutics and 14 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.63 beat Relay Therapeutics' score of 0.29 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryACADIA Pharmaceuticals beats Relay Therapeutics on 11 of the 17 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$744.85M$2.96B$5.24B$8.95BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-1.7145.5689.2317.34Price / Sales29.22265.291,255.2478.69Price / CashN/A192.9043.8235.97Price / Book0.763.965.324.79Net Income-$341.97M-$41.02M$122.69M$225.00M7 Day Performance0.22%-1.74%-0.16%1.52%1 Month Performance6.19%0.53%3.75%4.68%1 Year Performance-56.66%-1.69%27.40%20.89% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.4035 of 5 stars$4.46+3.2%$20.50+359.6%-57.2%$744.85M$25.55M-1.71330Analyst ForecastShort Interest ↑News CoverageHigh Trading VolumeACADACADIA Pharmaceuticals4.0025 of 5 stars$17.79+3.1%$25.25+41.9%-37.2%$2.96B$929.24M22.81510Short Interest ↑News CoverageVCELVericel1.7652 of 5 stars$59.89+0.7%$61.14+2.1%+56.1%$2.96B$226.84M998.33300Analyst ForecastAnalyst RevisionNews CoverageXENEXenon Pharmaceuticals2.7117 of 5 stars$38.24-0.4%$56.00+46.4%-15.6%$2.92B$9.43M-13.56210News CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.9589 of 5 stars$45.44-1.9%$81.43+79.2%-22.3%$2.90BN/A-35.222Analyst UpgradeNews CoverageMORMorphoSys0.2125 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730DNLIDenali Therapeutics4.4113 of 5 stars$19.34+1.3%$38.91+101.2%+28.1%$2.78B$330.53M-7.01430Analyst ForecastShort Interest ↑SWTXSpringWorks Therapeutics1.5074 of 5 stars$37.31-13.2%$70.00+87.6%-13.8%$2.78B$135.49M-9.62230Analyst RevisionNews CoverageMRUSMerus3.1317 of 5 stars$40.49-7.7%$85.64+111.5%+22.7%$2.77B$35.93M-10.2537Short Interest ↓News CoverageHigh Trading VolumeZLABZai Lab2.4959 of 5 stars$25.07-0.9%$55.00+119.4%+11.2%$2.74B$355.75M-9.052,175News CoverageBHCBausch Health Companies3.4532 of 5 stars$7.47-5.2%$7.75+3.7%-8.9%$2.70B$9.47B-15.5620,270Short Interest ↓News Coverage Related Companies and Tools Related Companies ACAD Alternatives VCEL Alternatives XENE Alternatives MLTX Alternatives MOR Alternatives DNLI Alternatives SWTX Alternatives MRUS Alternatives ZLAB Alternatives BHC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLAY) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLAY Stock Alerts